William Chou
Amministratore Delegato presso PASSAGE BIO, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
William Chou is currently the President, Chief Executive Officer & Director at Passage Bio, Inc. Prior to his current position, he served as the Chief Executive Officer at Aruvant Sciences, Inc. Dr. Chou completed his undergraduate degree at Princeton University, followed by an MBA from Yale School of Management.
He also holds a doctorate degree from the University of Pittsburgh School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
PASSAGE BIO, INC.
-.--% | 18/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di William Chou
| Società | Posizione | Inizio |
|---|---|---|
| PASSAGE BIO, INC. | Amministratore Delegato | 10/10/2022 |
Precedenti posizioni note di William Chou
| Società | Posizione | Fine |
|---|---|---|
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Amministratore Delegato | - |
Formazione di William Chou
| Yale School of Management | Masters Business Admin |
| University of Pittsburgh School of Medicine | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- William Chou
